Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bladder Cancer: early-phase trial registry
74 of 179 indexed Bladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #61 of 28,707 conditions by registered trial count.
179 US clinical trials · 74 currently recruiting · #61 of 28,707 conditions by registered trial count
Bladder Cancer: 179 US clinical trials tracked, 74 recruiting.
Bladder Cancer is the subject of 179 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition bladder-cancer
OPEN 74 | RECR 41% | LATE 14 | EARLY 84 | RANK #61 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Pediatric Obesity (41% recruiting · 46 trials)
Bladder Cancer lists 74 open slots (41% of 179 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bladder Cancer is recruiting above its size-band peers.
74 of 179 indexed trials (41.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Bladder Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 179 trials (9.5%). 92 distinct sponsors appear on at least one study for this condition label.
-
Typical Bladder Cancer enrolment sits around 98 participants.
Median target enrolment is 98 among the 176 trials that report a genuine target (sentinel values excluded). 90 of those (51.1%) plan for fewer than 100 participants.
-
Bladder Cancer research is mostly interventional.
131 interventional and 48 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
179 total, page 3 of 4
3 Tesla MRI in Patients With Bladder Cancer
University of Cincinnati
NCT00938145
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
Pangea Laboratory
NCT06870253
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
NCT03693014
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT02989584
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT03520491
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics
NCT04660929
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
Deepak Kilari
NCT04289779
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
M.D. Anderson Cancer Center
NCT00082706
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Memorial Sloan Kettering Cancer Center
NCT03504163
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
NCT05871008
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
M.D. Anderson Cancer Center
NCT00756639
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04386746
(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
Weill Medical College of Cornell University
NCT03837821
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03978624
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT04917809
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
NCT04018053
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02845323
Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients
University of Kansas Medical Center
NCT04046094
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
NCT05137262
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630
M.D. Anderson Cancer Center
NCT05055050
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
AstraZeneca
NCT02695121
The New England Bladder Cancer Study
National Cancer Institute (NCI)
NCT00342875
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Spectrum Pharmaceuticals
NCT00598806
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
Nucleix
NCT02700464
Survivin Urine mRNA Assay Risk of Bladder Cancer Study
Fujirebio Diagnostics
NCT00315653
Bladder Cancer Case Control Study of Arsenic in Water
National Institute of Environmental Health Sciences (NIEHS)
NCT00011518
A Comparison of the Studer Pouch Versus the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients
University of Southern California
NCT01008865
Eflornithine in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
NCT00003814
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Hoffmann-La Roche
NCT02108652
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
Matthew Milowsky, MD
NCT02643043
Screening for Bladder Cancer
Baylor College of Medicine
NCT00848627
Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology
Stanford University
NCT00801762
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
Health-Related Quality of Life in Patients With Bladder Cancer
David Latini
NCT00744744
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Sesen Bio
NCT02449239
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
Hoffmann-La Roche
NCT02951767
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT00582387
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
NCT04209114
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
NCT00003565
PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
Emory University
NCT01567462
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
Endo Pharmaceuticals
NCT01316874
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
NCT02553642
Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients
UNC Lineberger Comprehensive Cancer Center
NCT03156244
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
Eastern Cooperative Oncology Group
NCT00003129
Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer
University of Kansas Medical Center
NCT06337305
Physical Therapy in Pre-cystectomy Patients
UNC Lineberger Comprehensive Cancer Center
NCT05978570
FITBIT Study on Mobility and Readmissions After Radical Cystectomy
University of Pennsylvania
NCT04314778
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 45 |
| Phase 3 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bladder Cancer page
179 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bladder Cancer condition card totals 179 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.